Analysts See $-1.08 EPS for Anthera Pharmaceuticals (ANTH), Circor International (CIR) SI Increased By 0.64%

July 31, 2017 - By Maria Brooks

Circor International Incorporated (NYSE:CIR) had an increase of 0.64% in short interest. CIR’s SI was 1.35 million shares in July as released by FINRA. Its up 0.64% from 1.34M shares previously. With 65,300 avg volume, 21 days are for Circor International Incorporated (NYSE:CIR)’s short sellers to cover CIR’s short positions. The SI to Circor International Incorporated’s float is 8.34%. The stock decreased 8.30% or $4.71 on July 28, reaching $52.07. About shares traded. CIRCOR International, Inc. (NYSE:CIR) has risen 18.27% since July 31, 2016 and is uptrending. It has outperformed by 1.57% the S&P500.

Analysts expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to report $-1.08 EPS on August, 8.They anticipate $1.72 EPS change or 61.43% from last quarter’s $-2.8 EPS. After having $-2.03 EPS previously, Anthera Pharmaceuticals Inc’s analysts see -46.80% EPS growth. The stock decreased 4.14% or $0.06 on July 28, reaching $1.39. About shares traded. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has declined 93.94% since July 31, 2016 and is downtrending. It has underperformed by 110.64% the S&P500.

CIRCOR International, Inc. designs, makes and markets engineered products and sub-systems for markets, including gas and oil, aerospace, power and process, and industrial solutions. The company has market cap of $858.85 million. The Firm operates through two divisions: CIRCOR Energy (Energy segment (Energy)) and CIRCOR Advanced Flow Solutions (Advanced Flow Solutions segment (AFS)). It has a 78.94 P/E ratio. Energy provides engineered integrated flow control solutions, valves and services primarily in the gas and oil end market.

Among 6 analysts covering CIRCOR International (NYSE:CIR), 2 have Buy rating, 2 Sell and 2 Hold. Therefore 33% are positive. CIRCOR International had 16 analyst reports since November 3, 2015 according to SRatingsIntel. On Friday, July 14 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was downgraded by Seaport Global to “Sell” on Wednesday, June 21. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, July 4. KeyBanc Capital Markets downgraded CIRCOR International, Inc. (NYSE:CIR) on Friday, February 17 to “Sector Weight” rating. The rating was upgraded by Sidoti on Thursday, June 22 to “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, December 5. Suntrust Robinson initiated CIRCOR International, Inc. (NYSE:CIR) on Tuesday, November 3 with “Neutral” rating. The firm has “Neutral” rating given on Tuesday, November 3 by SunTrust. KeyBanc Capital Markets initiated the stock with “Sector Weight” rating in Tuesday, September 20 report. Stifel Nicolaus upgraded the shares of CIR in report on Monday, May 2 to “Buy” rating.

Since February 23, 2017, it had 0 insider buys, and 1 insider sale for $177,705 activity. Sharma Arjun had sold 2,930 shares worth $177,705.

Investors sentiment increased to 1.57 in Q4 2016. Its up 0.45, from 1.12 in 2016Q3. It increased, as 9 investors sold CIRCOR International, Inc. shares while 37 reduced holdings. 27 funds opened positions while 45 raised stakes. 15.91 million shares or 0.14% less from 15.94 million shares in 2016Q3 were reported. Amer Century Incorporated reported 92,976 shares stake. Citigroup Inc owns 26,062 shares or 0% of their US portfolio. Creative Planning owns 0% invested in CIRCOR International, Inc. (NYSE:CIR) for 100 shares. United Svcs Automobile Association holds 0.03% in CIRCOR International, Inc. (NYSE:CIR) or 124,710 shares. Sei reported 151 shares or 0% of all its holdings. Credit Suisse Ag owns 18,909 shares for 0% of their portfolio. Invesco Limited has 0% invested in CIRCOR International, Inc. (NYSE:CIR). Mason Street Advisors Ltd holds 0.01% of its portfolio in CIRCOR International, Inc. (NYSE:CIR) for 3,589 shares. Parkside State Bank And Tru invested in 10 shares or 0% of the stock. Manufacturers Life Ins Commerce The has invested 0.01% in CIRCOR International, Inc. (NYSE:CIR). Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% of its portfolio in CIRCOR International, Inc. (NYSE:CIR). 910,010 were accumulated by Dimensional Fund L P. 14,378 are held by Susquehanna Gp Llp. Bank Of Montreal Can reported 784 shares stake. Tower Rech Capital Ltd Liability Com (Trc) owns 0% invested in CIRCOR International, Inc. (NYSE:CIR) for 384 shares.

Investors sentiment increased to 1.13 in Q4 2016. Its up 0.13, from 1 in 2016Q3. It improved, as 11 investors sold Anthera Pharmaceuticals Inc shares while 19 reduced holdings. 13 funds opened positions while 21 raised stakes. 15.14 million shares or 28.64% less from 21.22 million shares in 2016Q3 were reported. Millennium Mgmt Limited Liability, New York-based fund reported 380,248 shares. Da Davidson And holds 0% or 112,780 shares. Hightower Advsr Limited Liability Corp, Illinois-based fund reported 73,100 shares. 36,413 are held by Tower Capital Lc (Trc). Kcg holds 0% or 271,239 shares in its portfolio. Moreover, Tiaa Cref Mngmt Ltd Co has 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Gru One Trading L P owns 0% invested in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) for 81,056 shares. Two Sigma Securities Ltd Liability Corp has 11,736 shares. Creative Planning reported 1,195 shares. Manufacturers Life Insurance Com The has 1,579 shares for 0% of their portfolio. Reilly Financial Advsrs Limited Company invested in 0% or 200 shares. Goldman Sachs Grp reported 0% of its portfolio in Anthera Pharmaceuticals Inc (NASDAQ:ANTH). Walleye Trading Limited Com stated it has 40 shares. Alliancebernstein L P has 21,600 shares for 0% of their portfolio. Bancshares Of New York Mellon Corporation reported 199,287 shares or 0% of all its holdings.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The company has market cap of $14.01 million. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. It currently has negative earnings. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions.